Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1984 1
1986 1
1987 1
1990 1
1995 1
1998 3
1999 2
2000 3
2001 2
2002 5
2003 10
2004 11
2005 5
2006 9
2007 4
2008 6
2009 4
2010 3
2011 4
2012 5
2013 6
2014 10
2015 7
2017 1
2018 1
2019 8
2021 3
2022 3
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
PI5P4Ks drive metabolic homeostasis through peroxisome-mitochondria interplay.
Ravi A, Palamiuc L, Loughran RM, Triscott J, Arora GK, Kumar A, Tieu V, Pauli C, Reist M, Lew RJ, Houlihan SL, Fellmann C, Metallo C, Rubin MA, Emerling BM. Ravi A, et al. Among authors: reist m. Dev Cell. 2021 Jun 7;56(11):1661-1676.e10. doi: 10.1016/j.devcel.2021.04.019. Epub 2021 May 12. Dev Cell. 2021. PMID: 33984270 Free PMC article.
Evaluation and prediction of drug permeation.
Pagliara A, Reist M, Geinoz S, Carrupt PA, Testa B. Pagliara A, et al. Among authors: reist m. J Pharm Pharmacol. 1999 Dec;51(12):1339-57. doi: 10.1211/0022357991777164. J Pharm Pharmacol. 1999. PMID: 10678488 Review.
PI5P4Kα supports prostate cancer metabolism and exposes a survival vulnerability during androgen receptor inhibition.
Triscott J, Reist M, Küng L, Mosele FC, Lehner M, Gallon J, Ravi A, Arora GK, de Brot S, Lundquist M, Gallart-Ayala H, Ivanisevic J, Piscuoglio S, Cantley LC, Emerling BM, Rubin MA. Triscott J, et al. Among authors: reist m. Sci Adv. 2023 Feb 3;9(5):eade8641. doi: 10.1126/sciadv.ade8641. Epub 2023 Feb 1. Sci Adv. 2023. PMID: 36724278 Free PMC article.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, Han JY, Dafni U, Cho BC, Yeo CM, Nadal E, Carcereny E, de Castro J, Sala MA, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi SMS, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres JM, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel RA, Peters S; ETOP 10-16 BOOSTER Collaborators. Soo RA, et al. Ann Oncol. 2022 Feb;33(2):181-192. doi: 10.1016/j.annonc.2021.11.010. Epub 2021 Nov 26. Ann Oncol. 2022. PMID: 34839016 Free article. Clinical Trial.
115 results